Targeting Trimethylamine N-Oxide for Cardiovascular Health In Liver Transplant Recipients

Launched by VIRGINIA COMMONWEALTH UNIVERSITY · Sep 12, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a substance called TMAO (trimethylamine N-oxide) to see how it affects heart health in people who have received a liver transplant. Even though liver transplants can save lives, many patients face a higher risk of heart disease afterward. Researchers want to understand how TMAO might play a role in heart problems for these patients, particularly those with chronic kidney disease.

To join the study, participants need to be over 18 years old, speak and understand English, and have had a liver transplant. However, there are some reasons why someone might not be eligible, such as having certain recent medical issues or complications related to their liver transplant. Those who participate will help researchers learn more about how to improve heart health after a liver transplant, which could lead to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged \> 18 years
• • Speak and understand English
• • Have received and LT
• Exclusion Criteria:
• • Acute cellular or chronic rejection within 3 months
• • Post-LT liver or non-liver related malignancy
• • Active viral hepatitis (B or C) or autoimmune hepatitis
• • Untreated biliary strictures or vascular complications (e.g. hepatic artery thrombosis)
• • Poorly controlled diabetes (HbA1c \>8.5%)
• • Relapse of alcohol use after LT
• • Follow a vegetarian or vegan diet
• • Current pregnancy
• • Unable to provide informed consent